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Abstract
Background: Current knowledge indicate that epirubicin administration in late pregnancy is almost devoid of any
fetal cardiotoxicity. We report a twin pregnancy complicated by breast cancer in which epirubicin administration
was causatively linked to the death of one twin who was small for gestational age (SGA) and in a condition of
oligohydramnios and determined the onset of a transient cardiotoxicity of the surviving fetus/newborn.
Case presentation: A 38-year-old caucasic woman with a dichorionic twin pregnancy was referred to our center at
20 and 1/7 weeks for a suspected breast cancer, later confirmed by the histopathology report. At 31 and 3/7 weeks,
after the second chemotherapy cycle, ultrasound examination evidenced the demise of one twin while cardiac
examination revealed a monophasic diastolic ventricular filling, i.e. a diastolic dysfunction of the surviving fetus who
was delivered the following day due to the occurrence of grade II placental abruption. The role of epirubicin
cardiotoxicity in the death of the first twin was supported by post-mortem cardiac and placental examination and
by the absence of structural or genomic abnormalities that may indicate an alternative etiology of fetal demise. The
occurrence of epirubicin cardiotoxicity in the surviving newborn was confirmed by the report of high levels of
troponin and transient left ventricular septal hypokinesia.
Conclusion: Based on our findings we suggest that epirubicin administration in pregnancy should be preceded by
the screening of some fetal conditions like SGA and oligohydramnios that may increase its cardiotoxicity and that,
during treatment, the diastolic function of the fetal right ventricle should be specifically monitored by a pediatric
cardiologist; also, epirubicin and desamethasone for lung maturation should not be closely administered since
placental effects of glucocorticoids may increase epirubicin toxicity.
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Background
The rapidly changing sociocultural and epidemiological
scene seems to increase in the near future the incidence
of breast cancer in pregnancy (BCP). Recent years have
witnessed a rising age at childbearing in Western
countries. In Italy the mean age at first delivery
increased from 29.8 years in 1995 to 31.5 years in 2013
[1]. At the same time, age at breast cancer onset in Italy
has reportedly decreased, and the incidence rates for
breast cancer in non-pregnant women under 45 years
increased from 20.06 per 100,000 in 1980 to 32.85 per
100,000 in 2015 [2]. The increasing age at childbearing
and younger age at breast cancer onset therefore imply
an increased risk of BCP.
Therapeutic approaches in BCP depend on tumor
stage, tumor biology, gestational age and patient’s
wishes. Systemic chemotherapy may be required before
or after surgery, and benefits for the mother must be
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compared with the potential harm to the fetus from in
utero exposure to chemotherapeutics. The adhesion of
patients with BCP to standard protocols based on the
administration of anthracyclines/alkylating agents is
highly recommended [3] as it grants patients with BCP
the same disease-free interval and overall survival rates
observed for non-pregnant patients with the same stage
of disease [4, 5].
All chemotherapeutics are potentially teratogenic or
may induce toxicity and organ dysfunction in the fetus
but current knowledge indicate that anthracyclines
including epirubicin administration in late pregnancy is
almost devoid of any fetal cardiotoxicity.
We report a case of dichorionic pregnancy complicated
by breast cancer, in which epirubicin administration was
associated to the death of one twin and to the contem-
porary evidence of a reversible cardiotoxicity of the
surviving fetus/newborn.
Case presentation
A 38-year-old caucasic woman, G1P0, with a dichorio-
nic twin pregnancy was referred to our center at 20
and 1/7 weeks for an excisional breast biopsy due to a
suspected breast cancer. The patient underwent right
external quadrantectomy with first level lymphnode
(LN) dissection. Neither family history for breast cancer
nor previous surgical interventions were reported. The
pathology report showed an invasive and poorly differenti-
ated (G3) ductal carcinoma not otherwise specified (NOS)
measuring 2 cm in diameter (pT1). Examined LN (10)
were negative for metastasis. The immunohistochemi-
cal evaluation [absent estrogen receptors (ER 0 %) and
C-erb-Neu expression, positive progesteron receptors
(PgR 40 %), and Ki-67 67 %] suggested a high risk of
relapse, prompting the start of adjuvant chemotherapy.
Maternal echocardiogram and laboratory tests were all
within the normal range. A chemotherapy regimen
based on epirubicin 90 mg/ m2 and cyclophosphamide
600 mg/m2 was started at a gestational age of 27 and
0/7 weeks; overall, the patient received 2 cycles of
chemotherapy on a 21 days outpatient basis.
A complete assessment of fetal well-being, including
the combined evaluations of fetal heart rate short term
variation (STV), the largest vertical pocket of amniotic
fluid (LVP-AF), pulsatility indices of the umbilical artery
(UA-PI), middle cerebral artery (MCA-PI) and ductus
venosus (DV-PIV), was performed before the start of
chemotherapy and weekly thereafter; control of fetal
growth pattern was scheduled every 3 weeks.
At baseline fetal ultrasound evaluation (26 and 6/7 weeks),
one twin (A) displayed normal anatomy and was scored as
small for gestational age (SGA), due to an estimated fetal
weight (EFW) < 10 percentile for gestational age (679 gr) in
the absence of signs of chronic placental dysfunction
including fetal circulatory redistribution (UA-PI: 1 and
MCA-PI: 1.5) and/or abnormal Doppler analysis of the
uterine arteries (mean resistence index: 0.4); for twin A a
condition of oligohydramnios was also evidenced (LVP-
AF: 15 mm).
Fetal surveillance was completely unremarkable for both
twin A and B during the two weeks that followed the first
cycle of chemotherapy. At 31 and 0/7 weeks, immediately
after the second chemotherapy cycle, all parameters of
twin B were scored as normal. Twin A presented an
unaltered growth pattern (EFW <10 percentile) and a per-
sistent oligohydramnios (LVP-AF of 12 mm) along with
normal UA-PI (1.19), MCA-PI (1.6) and STV (6.3 msec);
of note, right cardiac sections appeared dilated and an
abnormally high DV-PIV (1.1) was recorded, although
with no evidence of reverse flow (Fig. 1 Panel a). Antenatal
corticosteroids were administered (desamethasone
12 mg, 24 h apart). The following day (31 and 1/
7 weeks), STV values were normal (5.9 and 6.3 msec
for twins A and B, respectively).
At 31 and 3/7 weeks, ultrasounds evidenced the
demise of twin A; an echocardiogram of twin B showed
a monophasic diastolic filling addressing a diastolic
dysfunction of the right ventricle, together with a mild
hypokinesia of the ventricular septum (Fig. 1 Panel b).
At 31 and 4/7 weeks of gestation, twin B (2028 gr) was
delivered by emergency cesarean section due to grade II
placental abruption (Apgar score 7/9 at 1 and 5 min,
respectively).
The autopsy of twin A (900 g) did not evidence struc-
tural abnormalities; cardiac histology showed severe
myocardial interstitial edema with fiber dissociation and
sporadic vacuolar myocyte degeneration (Fig. 1 Panel c).
The only other remarkable findings were found in twin
A extravillous throphoblast (hypertrophic vacuolization
and nuclear pleomorphism) and chorionic villi (inter-
stitial edema and fibrinoid necrosis) (Fig. 1 Panel D).
Comparative genomic hybridization (CGH) analysis, per-
formed on umbilical cord extracted DNA, did not show
any genomic rearrangement.
Routine laboratory tests obtained for twin B during
the first day of life (DOL) were normal; however, a docu-
mented significant septal hypokinesia (Fig. 1 Panel e),
confirmed by a pediatric cardiologist with 20 years of
experience in perinatal cardiac assessment, was associ-
ated to extremely high concentrations of troponin (Tn1)
(Tn1: 0.21 μg/L; reference < 0.0014 μg/L); Tn1 was still
abnormally elevated on DOL 19 (Tn1: 0.06 μg/L) but
progressively decreased back to normal values on DOL
40. Pediatric cardiology examinations were regularly
performed (every four weeks) up to six months of age
and confirmed regular post-natal cardiac function.
Overall, the causative role of epirubicin cardiotoxicity
in the death of twin A is supported by various evidences
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including: 1- the post-mortem cardiac examination
revealing the hallmarks of subacute anthracycline tox-
icity, i.e. massive interstitial edema without cellular infil-
trates and myofibrillar damage/vacuolization [6]; 2- the
histologic findings in both chorionic villi and extravillous
throphoblast, well fitting the described placental effects
of anthracycline exposure [7]; 3- the manifestation of
acute myocardial diastolic dysfunction, evidenced by the
enlarged right cardiac chambers and an elevated ductus
venosus pulsatility index, preceding fetal death; 4 – the
absence of structural or genomic abnormalities that may
indicate an alternative etiology of fetal demise. Of note,
neither arterial Doppler nor STV evaluation anticipated
the impending fetal demise.
Conclusions
The first trimester is the most critical time regarding
teratogenic effects. The blastocyst is resistant to terato-
genic drugs in the first 2 weeks from conceptions whereas
the administration of chemotherapy during organogenesis
from 4 to 13 weeks of pregnancy is associated with an
increased risk of miscarriage or congenital malformations
[8] as largely documented from case reports, case series
and collected reviews [9–11]. Second and third trimester
chemotherapeutics exposure after the end of organogen-
esis, does not usually increase the teratogenic risk but may
cause neurocognitive development disorders and in-
creasing risk of intrauterine growth retardation (IUGR),
pre-term labour and low birth weight [12–16].
According to SOGC guidelines, we should administer
the standard regimens based on a combination of
anthracyclines/alkylating agents after the end of the first
trimester [17].
The first prospective collection of data addressing the
issue of antracyclines safety profile in pregnancy was
first reported by the Texas MD Anderson Cancer Center
back in 1999. These authors treated 24 pregnant patients
with primary or recurrent cancer of the breast managed
with a standardized protocol of 5-fluorouracil + doxo-
rubicin + cyclophosphamide (FAC) chemotherapy in the
second and third trimester of pregnancy and did not
report an increased rate of congenital anomalies [18]. In
Fig. 1 Panel a: Sonogram showing a significantly elevated DV-PIV in twin A. Panel b: Echocardiogram of twin B. Four chamber view. PW Doppler of
flow through tricuspidal valve. Monofasic diastolic filling of the right ventricle; hallmark of diastolic function. Panel c: Myocardial severe interstitial
edema with fiber dissociation and sporadic vacuolar myocyte degeneration of the twin A fetal heart. Panel d: Hypertrophic vacuolization and nuclear
pleomorphism of extravillous throphoblast, with interstitial edema and areas of fibrinoid necrosis of placenta (✷). Panel e: Neonatal echocardiography
of twin B. M-mode long axis of the left ventricle. Evidence of mild septal hypokinesia with an overall preserved global contractility
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the same year, a French survey reporting 12 patients
with BCP alternatively treated with FAC, 5-fluorouracil +
epirubicin + cyclophosphamide (FEC), epirubicin + cyclo-
phosphamide (EC) or doxorubicin + cyclophosphamide
(AC) evidenced only one case of intrauterine death at
30 weeks of gestation [19]. In a retrospective, cohort study
evaluating the fetal risks involved in the administration
of cancer chemotherapy during gestation, one fetus died
after second trimester exposure to epirubicin, vincristine
and prednisone but no malformation was detected [20].
Hahn et al. extended the previous evidences from the MD
Anderson Cancer Center and confirmed the absence of
congenital birth defects in fetuses exposed to anthracy-
clines chemotherapy in utero; indeed, only three children
reported congenital malformations in a group of 57
women treated up to 2006, with a median number of four
FAC cycles given during pregnancy; one neonate was born
with Down syndrome, one with ureteral reflux, and a
third with club foot [21]. Ring et al. evaluated 16 out
of 28 BCP patients receiving anthracyclines-based
chemotherapy during pregnancy without reporting any
congenital birth defect [22].
The German Breast Group issued the first Inter-
national Recommendations on BCP and confirmed the
safety of anthracyclines [23]. An international consensus
meeting held in 2010 confirmed that anthracyclines can
be used in the setting of BCP [24] and RCOG guidelines
assigned an Evidence level 3 to the statement that
anthracycline-based chemotherapy in the second and
third trimesters can be administered with minimal risk
to the developing fetus [25].
Anthacyclines display well-known cardiotoxic effects:
age, cumulative dose and previous radiotherapy increases
the rates of cardiac damage in children and adults [26].
The molecular mechanisms underlying antracyclines
cardiotoxicity are not fully understood, but include al-
terations of cell membranes fluidity and ion transport
with generation of reactive oxygen species by iron-
anthracycline complexes, leading to lipid peroxidation
and membrane damage [27] and the impairment of DNA
repair through the interaction with the topoisomerase-II-
beta enzyme in myocytes [28]. Increasing evidences show
that the extracellular matrix plays a complex and diverse
role in some processes initiated by anthracyclines that
finally lead to cardiac damage [29]. Notably, fetal myocar-
dium is theoretically more vulnerable to damage by
chemotherapeutics because fetal myocytes are smaller
than adult ones, and contain fewer sarcomeres and
mitochondria [30].
Fetal safety during the administration of anthracycline-
based chemotherapy in pregnancy is of theoretical
concern because anthracyclines can cross the placenta,
even if their fetal plasma concentrations are lower than
those found in the mother, and have cumulative toxicity
[31]. Available data provide only limited experimental
and clinical data on the transplacental transfer of these
chemotherapeutics in pregnant women; in a baboon
model, fetal plasma concentrations of doxorubicin, epir-
ubicin and paclitaxel were about 7.5 %, 4.0 %, and 1.4 %,
of the respective maternal concentrations [32]. Fetal
blood samples from pregnant rats receiving doxorubicin
showed a plasmatic concentration that was 6.2 % that
of the mother; interestingly, neither Doppler analysis
nor heart microstructure or cellular DNA turnover and
apoptosis were influenced by doxorubicin exposure [33].
Owing to the molecular weight of doxorubicin is 580
dalton, there is an incomplete transfer of the drug across
the placental barrier [8]. However, the transplacental
passage cannot be simply predicted from the physical-
chemical properties of the drugs like the molecular
weight. Really, while assessing fetal plasma drug concen-
trations, the functional expression of many members of
the ATP-binding cassette (ABC) efflux transporters that
are highly expressed in the human placenta, should be
adequately considered; indeed, these transporters pre-
vent the trans-placental transfer of cytotoxic compounds
present in the maternal circulation, therefore protecting
the fetus [34, 35]; specifically, anthracyclines and taxanes
are substrates for ABC-transporters like the major
placental drug-transporting P-glycoprotein, that keeps
low the fetal plasma concentrations of these harmful
compounds [36].
Anthracyclines do not collectively share the same low
rate of transplacental transfer. Indeed, idarubicin, being
more lipophilic than other antracyclines, easily crosses
the placenta; Germann reported one fetal death and one
case of reversible heart dysfunction in a group of
patients affected by acute myeloid leukemia receiving
idarubicin-based chemotherapy during the third trimes-
ter of pregnancy [37]. Similarly, Baumgartner reported
one case of reversible fetal cardiomyopathy following the
use of idarubicin during pregnancy [38] while the occur-
rence of a severe idarubicin-related cardiotoxicity in a
newborn was described in a swiss study [39]. Altogether,
these findings suggest a close fetal monitoring during
idarubicin based chemotherapy; long-term outcomes of
idarubicin exposed children need further investigations.
Unlike idarubicin, doxorubicin and epirubicin, due to
their low levels in fetal plasma, may be administered
during the second and third trimesters without signifi-
cant risk of fetal myocardial dysfunction. At first, clini-
cians gained some experience on the safety profile of
these two antracyclines from case reports and small case
series [40]. Further reassuring evidence was granted by
an Italian review reporting that only 13/out of 403 (3 %)
children exposed to these anthracyclines during late
pregnancy developed short-term cardiac complications
[41]. Azim et al. reported that different epirubicin and
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doxorubicin regimens administered in adjuvant, neoadju-
vant and metastatic settings (23 patients and 3 patients,
respectively) did not adversely affect the course of
pregnancy or fetal/neonatal outcome [42]. In a small
cohort of patients, even a dose-dense antracyclines
chemotherapy administered every two weeks did not
involve a higher risk of fetal complications [43].
In a prospective case–control clinical study, Gziri
found that maternal and fetal cardiac functions were not
significantly hampered by anthracyclines exposure in
pregnancy but rather displayed only minor changes of
the myocardial performance index and the tricuspid
inflow devoid of any clinical relevance [44].
Notably, epirubicin in pregnancy has a shorter terminal
half-life than doxorubicin due to its combined glucuroni-
zation by the liver and the placenta [45] and therefore
displays a better therapeutic index with fewer systemic
and cardiotoxic effects. In an Austrian study, all three
patients managed at the University Hospital of Vienna
with six courses of FEC neoadjuvant chemotherapy de-
livered healthy newborns [46]. Others case reports on
multidrugs regimens including epirubicin as adjuvant
treatment for pregnant women with high-risk breast
cancer failed to show any fetal cardiotoxicity [47, 48].
Some authors report that weekly epirubicin schedule
seems particularly safe because it decreases the potential
adverse events and simultaneously facilitates a close
monitoring of pregnancy [49].
Overall, anthracyclines emerge as theoretically safe dur-
ing the late trimesters of pregnancy, fetal concentrations
being 100/1000-fold lower than adults as a result of the
high molecular weight, the hydrophilic charge leading to a
limited transplacental passage and the active clearance
operated by the placental P-glycoprotein transporter.
Indeed, despite the difficulty of comparing different agents
and schedules used for BCP, fetal cardiotoxicity never
emerged as a major problem of anthracyclines administra-
tion; in particular the available evidences indicate that
epirubicin harmful effects on fetal heart are very lim-
ited with only one reported case of transient ventricular
hypokinesia [41].
In this otherwise quite reassuring scenario, we provide
evidence that, in a twin pregnancy complicated by breast
cancer, epirubicin administration was causatively linked
to the death of one twin and to the onset of a reversible
cardiotoxicity of the surviving fetus/newborn.
The ultimate cause of twin A great susceptibility to
the cardiotoxic action of epirubicin remains elusive.
Anthracyclines are concentrated up to nine times more
in the amniotic fluid than in fetal plasma [32]; in this
regard, the presence of oligohydramnios and the histo-
logic evidences of altered extravillous throphoblast and
chorionic villi, suggest the a putative contribution of an
abnormal amniotic fluid dynamics to the increased/
prolonged toxicity of epirubicin in twin A. Further
support to the hypothesis of an hampered epirubicin
farmacokynetics is offered by the circumstantial evi-
dences that the succumbing SGA twin A died shortly
after the administration for lung maturation of gluco-
corticoids; these steroids, among a myriad of actions,
are known to downregulate the throphoblast expression
of the detoxifying P-glycoprotein transporter [50]. Epirubi-
cin cardiotoxicity was also evident, although to a lesser
extent, in Twin B as shown by 1- the prenatal findings of
an isolated mild right ventricular diastolic dysfunction
(reflecting the greater after load of this ventricle in the
fetal circulation) and 2- postnatal recording of in-
creased Tn1, associated to a transient left ventricular
septal hypokinesia [51].
In conclusion, with reference to the above men-
tioned considerations, we suggest that a precautional
use of epirubicin in pregnancy should include; 1- the
screening of oligohydramnios since this condition may
putatively increase epirubicin cardiotoxicity 2- a
timely surveillance by a pediatric cardiologist of the
diastolic function of the fetal right ventricle, because
the other indices of fetal well being are poorly pre-
dictive of an impending fetal cardiac decompensation
3- the avoidance of a close administration of epirubi-
cin and desamethasone since glucocorticoids may
hamper placental metabolism of epirubicin, ultimately
increasing its toxicity.
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